Why Berkshire Soured on Johnson & Johnson

Our health-care roundtable gathers The Motley Fool's top health-care analysts to discuss the sector's biggest stories in a free flowing and highly opinionated format.

In this portion of the video, the guys speculate on what Johnson & Johnson should be doing for shareholders, and why the company's lack of interest in share buybacks now might be a reason Warren Buffett's Berkshire Hathaway walked away.

In the world of health care, companies simply don't come any bigger than Johnson & Johnson. Many own the stock, but few understand its story. Offering everything from baby powder to biologics, the company is sometimes criticized for spreading itself too thin and becoming nothing more than a bloated corporate whale. Is this true, or is J&J a well-diversified giant that's perfect for your portfolio? Make sure you understand the full story behind the stock, along with its key opportunities and risks, by checking out our brand-new premium report on Johnson & Johnson. To claim your copy, simply click here now for instant access.

The article Why Berkshire Soured on Johnson & Johnson originally appeared on Fool.com.

Brenton Flynn and David Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.